Tenofovir Alafenamide (taf) - Pharma

Relevant Publications

Observational pilot study of switching from entecavir to tenofovir alafenamide in patients with chronic hepatitis B.

Issue Release: 2025

Adherence and forgiveness of two modern ART regimens: lamivudine/dolutegravir and emtricitabine/tenofovir alafenamide/rilpivirine.

Issue Release: 2025

HIV and adipose tissue: A long history linked to therapeutic classes of antiretrovirals.

Issue Release: 2024

Dolutegravir- Versus Efavirenz-Based Treatment in Pregnancy: Impact on Red Blood Cell Folate Concentrations in Pregnant Women and Their Infants.

Issue Release: 2024

Choice of antiretroviral therapy has low impact on weight gain.

Issue Release: 2024

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B.

Issue Release: 2024

A Phase 1 Clinical Trial to Assess the Safety and Pharmacokinetics of a Tenofovir Alafenamide/Elvitegravir Insert Administered Rectally for HIV Prevention.

Issue Release: 2024

Profiling the Interaction between Human Serum Albumin and Clinically Relevant HIV Reverse Transcriptase Inhibitors.

Issue Release: 2024

Angiolipoma associated with antiretroviral switch therapy: a case report.

Issue Release: 2024

Effects of Antiretroviral Treatment on Central and Peripheral Immune Response in Mice with EcoHIV Infection.

Issue Release: 2024

Worldwide study of the taste of bitter medicines and their modifiers.

Issue Release: 2024

Evaluation of genotoxic and mitotoxic effects of TAF-loaded chitosan nanoparticles in HepG2 cells.

Issue Release: 2024

Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV.

Issue Release: 2024

Changes in blood lipid levels and influencing factors among treatment-naïve adult male HIV/AIDS patients following BIC/FTC/TAF vs. 3TC+EFV+TDF.

Issue Release: 2024

Five-year Treatment with Tenofovir Alafenamide Achieves High Rates of Viral Suppression, Alanine Aminotransferase Normalization, and Favorable Bone and Renal Safety in Chinese Chronic Hepatitis B Patients.

Issue Release: 2024

Pharmacokinetics of tenofovir alafenamide, emtricitabine, and dolutegravir in a patient on peritoneal dialysis.

Issue Release: 2024

Evaluation of Pharmacokinetics of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil (TDF) in Pregnant and Postpartum Women in South Africa: PrEP-PP PK Study.

Issue Release: 2024

Comments on \"High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre-existing HIV resistance and suboptimal adherence\".

Issue Release: 2024

Comparative evaluation of adverse drug reactions for tenofovir alafenamide and tenofovir disoproxil fumarate using the FAERS Database: a disproportionality analysis.

Issue Release: 2024

Lipid and glucose profiles in pregnant women with HIV on tenofovir-based antiretroviral therapy.

Issue Release: 2024

What is Generic Competition?

Why is Medication Adherence Important?

How are ADEs Detected and Reported?

What Role Does Cellular Stress Play in Disease?

Why is Transitional Care Important in Pharma?

What is Geriatric Care in Pharma?

How Are Participants Protected?

What is Cellular Stress?

What is Patient Education in Pharma?

What Strategies do Brand-Name Companies Use to Delay Generic Entry?

Tenofovir Alafenamide (taf) - Pharma

Relevant Publications

Partnered Content Networks

Relevant Topics